 |
PolyMedix Provides Update on PMX-60056 Program
May 10, 2012
|
15.1 KB |
|
| |
RADNOR, Pa., May 10, 2012 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company focused on developing innovative therapeutic drugs to treat patients with serious acute-care conditions, today announced an update on the development status of its anticoagulant reversing agent, PMX-60056. PolyMedix has stopped enrollment in two clin...
|
|
PolyMedix Announces Positive Results From Phase 2 Clinical Trial With PMX-30063 First-in-Class Defensin-Mimetic Antibiotic
Apr 23, 2012
|
68.3 KB |
|
| |
Study in patients with Acute Bacterial Skin and Skin Structure Infections showed all three doses to have high clinical response rates and to be safe
Conference Call Today at 9:00 a.m. ET
RADNOR, Pa., April 23, 2012 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company focused on developing innovative therapeuti...
|
|
PolyMedix to Review Full Results From Phase 2 Clinical Trial With PMX-30063 Defensin-Mimetic Antibiotic
Apr 20, 2012
|
17.5 KB |
|
| |
RADNOR, Pa., April 20, 2012 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company focused on developing innovative therapeutic drugs to treat patients with serious acute-care conditions, has scheduled a conference call and webcast for Monday, April 23rd at 9:00 AM Eastern Time. At that time, management will review the full resul...
|
|
PolyMedix Restructures Its Debt and Secures $12 Million Credit Facility
Apr 10, 2012
|
17.5 KB |
|
| |
RADNOR, Pa., April 10, 2012 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company focused on developing innovative therapeutic drugs to treat serious acute-care conditions, announced that it has entered into a loan and security agreement with MidCap Financial LLC. Through the secured term loan, MidCap will provide PolyMedix with...
|
|
PolyMedix's PMX-30063 First in Class Defensin-Mimetic Antibiotic Demonstrates Activity Against Drug-Resistant Bacterial Pathogens
Apr 2, 2012
|
15.6 KB |
|
| |
RADNOR, Pa., April 2, 2012 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company focused on developing innovative therapeutic drugs to treat serious acute-care conditions, announced today that its lead defensin-mimetic antibiotic, PMX-30063, has shown activity against 1,000 worldwide strains of Gram-positive staphylococci and st...
|
|
PolyMedix to Present at the Roth 24th Annual Growth Stock Conference
Mar 5, 2012
|
14.6 KB |
|
| |
RADNOR, Pa., March 5, 2012 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company focused on developing innovative therapeutic drugs to treat serious acute-care conditions, will be presenting at the Roth 24th Annual Growth Stock Conference. The Conference will take place March 11-14, 2012 Laguna Niguel, CA.
PolyMedix will...
|
|
PolyMedix to Present at the Cowen 32nd Annual Health Care Conference
Feb 28, 2012
|
14.9 KB |
|
| |
RADNOR, Pa., Feb. 28, 2012 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company focused on developing innovative therapeutic drugs to treat serious acute-care conditions, announced today that Nicholas Landekic, the Company's President & CEO will present at the Cowen and Company 32nd Annual Health Care Conference on Tuesday, Mar...
|
|
PolyMedix to Present at the 14th Annual BIO CEO and Investor Conference
Feb 7, 2012
|
15.1 KB |
|
| |
RADNOR, Pa., Feb. 7, 2012 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company focused on developing innovative therapeutic drugs to treat serious acute-care conditions, will be presenting at the 14th Annual BIO CEO and Investor Conference. The Conference, which is the largest investor conference focused on established and emer...
|
|
PolyMedix Defensin-Mimetic Antimicrobial Compounds Show Activity Against Oral Candida Fungus and Malaria
Jan 20, 2012
|
18.9 KB |
|
| |
RADNOR, Pa., Jan. 20, 2012 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company focused on developing innovative therapeutic drugs to treat serious acute-care conditions, announced today encouraging in vivo and in vitro data for its novel, defensin-mimetic antimicrobial compounds, which included studies showing efficacy in anim...
|
|
PolyMedix Completes Enrollment in Phase 2 Trial With PMX-30063 Defensin-Mimetic Antibiotic
Jan 4, 2012
|
15.8 KB |
|
| |
RADNOR, Pa., Jan. 4, 2012 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company focused on developing innovative therapeutic drugs to treat serious acute-care conditions, announced that it has completed enrollment of 215 patients in its multinational Phase 2 clinical trial designed to evaluate PMX-30063 defensin-mimetic antibiot...
|
|
PolyMedix Announces Encouraging Interim Results From Multinational Phase 2 Clinical Trial With PMX-30063 Defensin-Mimetic Antibiotic
Dec 7, 2011
|
19.3 KB |
|
| |
Efficacy and Safety Demonstrated in All Evaluated Dose Groups
First Clinical Study with New Class of Antibiotic in Patients with S. aureus ABSSSI Infections
Conference Call Today at 9:00 am ET
RADNOR, Pa., Dec. 7, 2011 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company focused on developing new therape...
|
|
PolyMedix to Review Interim Results From Multinational Phase 2 Clinical Trial With PMX-30063 Defensin-Mimetic Antibiotic
Dec 6, 2011
|
16.5 KB |
|
| |
RADNOR, Pa., Dec. 6, 2011 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTC BB: PYMX), a biotechnology company focused on developing new therapeutic drugs to treat life-threatening infectious diseases and acute cardiovascular disorders, has scheduled a conference call and webcast for Wednesday, December 7 at 9:00 AM Eastern Time. At that time, management wi...
|
|
PolyMedix Launches New Website
Dec 6, 2011
|
15.5 KB |
|
| |
RADNOR, Pa., Dec. 6, 2011 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTC BB:PYMX), a clinical-stage biotechnology company focused on developing new therapeutic drugs to treat life-threatening infectious diseases and acute cardiovascular disorders, is pleased to announce the launch of its redesigned company website at www.polymedix.com. The enhanced site ...
|
|
PolyMedix to Present at the Lazard Healthcare Conference
Nov 8, 2011
|
16.7 KB |
|
| |
RADNOR, Pa., Nov. 8, 2011 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company focused on developing new therapeutic drugs to treat life-threatening infectious diseases and acute cardiovascular disorders, will be presenting at the Lazard 8th Annual Healthcare Conference. The Conference will take place November 15-16, 2011 at Th...
|
|
PolyMedix Presents PMX-30063 Antibiotic Data at the 49th Annual Meeting of the Infectious Disease Society of America
Oct 24, 2011
|
18.7 KB |
|
| |
RADNOR, Pa., Oct. 24, 2011 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a clinical stage biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and life-threatening infectious diseases, presented clinical and pre-clinical data related to the spectrum of activity and safety of its novel defensi...
|
|
PolyMedix Selected as Best Mid-Stage Product Development Company at Annual Life Sciences Awards
Oct 6, 2011
|
14.9 KB |
|
| |
RADNOR, Pa., Oct. 6, 2011 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTC BB: PYMX), an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and life-threatening infectious diseases, was named the winner of Philadelphia Business Journal's Best Mid-Stage Product Development Company award.
...
|
|
PolyMedix Initiates Phase 1B/2 Dose-Response Clinical Trial to Reverse the Anticoagulant Activity of Enoxaparin with PMX-60056
Sep 27, 2011
|
16.5 KB |
|
| |
RADNOR, Pa., Sept. 27, 2011 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and life-threatening infectious diseases, has initiated a Phase 1B/2 clinical study to evaluate the safety and efficacy of PMX-60056 in reversing the anti...
|
|
PolyMedix Presents Antibiotic Data in Oral Session at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
Sep 19, 2011
|
12.4 KB |
|
| |
Radnor, PA (September 19, 2011) - PolyMedix, Inc. (OTCBB:PYMX), an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and life-threatening infectious diseases, today announced the presentation of data at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (...
|
|
PolyMedix to Present at the UBS Global Life Sciences Conference
Sep 13, 2011
|
9.4 KB |
|
| |
Radnor, PA (September 13, 2011) - PolyMedix, Inc. (OTC BB: PYMX), an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and life-threatening infectious diseases, will be presenting at the UBS Global Life Sciences Conference. The Conference will take place September 19-21...
|
|
PolyMedix Provides Updates on Lead Clinical Programs
Sep 12, 2011
|
11.4 KB |
|
| |
Radnor, PA (September 12, 2011) -PolyMedix, Inc. (OTCBB:PYMX), an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and life-threatening infectious diseases, today provided an update for its two lead programs, heptagonist PMX-60056 and defensin-mimetic antibiotic PMX-30063....
|
|
|
delicious
Digg
Facebook
LinkedIn
Twitter
Yahoo! Buzz
